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ABSTRACT: Originally discovered almost a century ago, cocrystals continue to gain interest in the modern day due to their
ability to modify the physical properties of solid-state materials, particularly pharmaceuticals. Intensification of cocrystal
research efforts has been accompanied by an expansion of the potential applications where cocrystals can offer a benefit. Where
once solubility manipulation was seen as the primary driver for cocrystal formation, cocrystals have recently been shown to
provide attractive options for taste masking, mechanical property improvement, and intellectual property generation and
extension. Cocrystals are becoming a commercial reality with a number of cocrystal products currently on the market and more
following in registration and clinical trial phases. Increased commercialization of cocrystals has in turn necessitated additional
research on methods to make cocrystals, with particular emphasis placed on emerging technologies that can offer
environmentally attractive and efficient options. Methods of producing cocrystals and of harnessing the bespoke physical
property adjustment provided by cocrystals are reviewed in this article, with a particular focus on emerging trends in these areas.
1. INTRODUCTION
Cocrystals are solids that are neutral crystalline single phase
materials composed of two or more different molecular and/or
ionic compounds generally in a stoichiometric ratio which are
neither solvates nor simple salts.1 If at least one of the
coformers is an API and the other is pharmaceutically
acceptable, then it is recognized as a pharmaceutical cocrystal.2
Cocrystals of different stoichiometry with the same coformer
are possible, as illustrated by the carbamazepine:4-amino-
benzoic acid cocrystal system, which can exist in 1:1, 2:1, and
4:1 stoichiometric configurations.3 A cocrystal has a different
crystal structure to either of the starting materials and as a
result different physicochemical properties. Cocrystals are
attractive because the cocrystal solid can be designed to have
superior physical properties to either of the pure starting
molecules. Physical property improvement via cocrystal
formation has been demonstrated for solid explosives,4
agrochemicals,5 pigments,6 and, particularly, pharmaceuti-
cals.7−12
Physical property improvement is of particular interest to
pharmaceuticals as the vast majority of medicines are delivered
as solid forms. The physical properties of the solids contained
within a pharmaceutical drug product will have a direct impact
on the processing, delivery, and, ultimately, performance of the
medicine. To provide a classic example, crystal structure
directly affects the solubility of a given solid in solution. Drug
products require a certain solubility to be bioavailable in the
body. It is estimated that 40% of existing drug products and up
to 90% of new chemical entities have limited aqueous
solubility13 and hence cannot be delivered to the body using
conventional techniques. Cocrystal formation with a suitable
coformer offers the potential of improved solubility via
modification of the underlying crystal structure, thus
potentially rendering the compound bioavailable. As cocrystal
research has expanded, it has available a range of application
areas for physical property manipulation through cocrystal
formation. Improvements in solubility, stability, bioavailability,
and mechanical properties have been well documented,14,15
and emerging applications such as taste masking and
intellectual property extension are being explored.
Research in cocrystal structure and applications has shown
an exponential increase in the past decade, evident in the
number of cocrystal structures deposited in the Cambridge
Structural Database16 and cocrystal related patent applications.
In light of this, it is surprising that cocrystal preparation
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methods have remained, until relatively recently, largely poorly
defined. Limited research attention has been directed
specifically at cocrystal preparation, and this topic receives
little detail in the majority of existing publications. Initial
cocrystal related research efforts centered on elucidation of the
crystal structure of cocrystal and bonding mechanisms,
requiring high quality single crystals from cocrystal samples.
This was typically achieved using trial and error approaches
based on solvent evaporation that serendipitously yielded
cocrystals, on occasion. A universal approach was lacking. As
experimentation with cocrystal systems increased, the demand
for larger quantities of cocrystal material accompanied it.
Solution based cocrystallization routes were employed,
requiring knowledge of the solubility of both starting materials
in the solvent of choice, often supplied in the format of a
ternary phase diagram. Again, methods used were inconsistent
from research paper to research paper, and no universal
approach was practiced.
Today, a wide range of successful cocrystal preparation
methods have been documented: solvent evaporation, solid
state grinding, solution crystallization, slurry conversion, melt
crystallization, hot melt extrusion, and spray crystallization.
But, there is little consistency in the application of different
preparation methods or even in the terminology used to
describe the same. Details such as solvent choice, concen-
tration of the target molecule/coformer, equilibration time,
and the recovery process are often not provided. This makes it
difficult to repeat or compare cocrystal preparation methods
and must be confusing to a newcomer to this research area.16
The objective of this review is to systematically describe all
reported cocrystal preparation routes and applications in a
single location in an effort to standardize progress achieved to-
date in this evolving area.
2. COCRYSTAL PRODUCTION
Cocrystal production routes can be broadly categorized as
solid-state or solution based. Solid-state methods can be
differentiated as methods using very little or no solvent, with
solution based methods representing production routes that
involve a large excess of solvent necessitating a subsequent
isolation stage to separate the crystalline product from the
mother liquor.
2.1. Solid State Methods. 2.1.1. Contact Formation. The
spontaneous formation of cocrystals via mixing of pure API
and coformer under a controlled atmospheric environment has
been reported.17−19 In this method, no mechanical forces are
applied during cocrystallization.20,21 However, in some cases,
brief grinding of pure components individually before mixing
has been done.20 Rodriguez-Hornedo et al. studied the effect
of premilling of the starting materials on the cocrystallization
rate of carbamazepine and nicotinamide.20 It was shown that
the cocrystallization rate in the case of premilled reactants was
markedly faster than that of unmilled reactants (12 versus 80
days, respectively). Moreover, higher cocrystallization rates
have been reported for the same system at higher temperatures
and relative humidity, regardless of the mechanical activa-
tion.20 Sarcevica et al. reported the formation of an isoniazid-
benzoic acid cocrystal via spontaneous cocrystallization.22
They reported that the rate of reaction was considerably
increased at higher premilling frequencies of the pure
reactants.22 Moreover, Ibrahim et al. studied the effect of the
particle size of starting materials on spontaneous cocrystalliza-
tion of urea and 2-methoxybenzamide (2-MB). It has been
shown that smaller particle size distributions lead to faster
cocrystal formation. A rapid increase in cocrystallization rate
was observed in the case of the small particle size distribution
of 20−45 μm, where no buried eutectic or amorphous
intermediate phase was detected.21 The mechanism of
cocrystallization in the presence of moisture at deliquescent
conditions consists of three stages of (1) moisture uptake, (2)
dissolution of reactants, and (3) cocrystal nucleation and
growth23 (Figure 1).
Berry et al. used hot-stage microscopy for cocrystal
screening. They used the Kofler method to successfully
probe the binary phase behavior of a given cocrystal system,
revealing potential cocrystal phases in five API mixtures. In this
work, nicotinamide was chosen as a molecular scaffold former
with a series of APIs, e.g., fenbufen, flubiprofen, ibuprofen,
ketoprofen, and salicylic acid. In this method, one component
is melted then allowed to solidify, before another component is
brought into contact with it and a proportion of the first
component is solubilized. Thus, after recrystallization of all
materials, a zone of mixing is created. This is comparable to the
binary phase diagram of the two components. With this
method, they were able to identify the formation of
nicotinamide:ibuprofen, nicotinamide:salicylic acid, nicotina-
mide:flubiprofen, and nicotinamide:fenbufen.
2.1.2. Solid State Grinding. Solid state grinding methods
have been used successfully to generate cocrystal powder
samples. Two formats are practiced: neat (dry) grinding and
liquid assisted grinding. Neat grinding involves the combina-
tion of the target molecule and coformer in their dry solid
forms with the application of pressure through manual (mortar
and pestle) or mechanical (automated ball mill) means. Dry
grinding is distinct from melt crystallization as the solid
starting materials are not expected to melt during grinding.
The temperature achieved during grinding is often monitored
to ensure the same, and will often be reported. Two
sulphathiazole:carboxylic acid cocrystals were prepared by
grinding stoichiometric equivalents of sulphathiazole with the
required carboxylic acid for 90 min in a Retsch mixer mill at a
25 Hz frequency with the temperature not allowed to exceed
37 °C.24
There is an efficiency associated with solid state grinding,
relative to solution based methods, in that yield is not lost to
the solvent due to solubility.25
Issues with dry grinding can include failure to form a
cocrystal, incomplete conversion to the cocrystal, and
crystalline defects with possible generation of some amorphous
Figure 1. Illustration of the moisture uptake process leading to
deliquescence, reactant dissolution, and cocrystal formation. A and B
are cocrystal reactants, Ds is solid deliquescent additive, and Dl is the
solution phase created by deliquescence at relative humidity greater
than deliquescence relative humidity. (Reprinted with permission
from ref 23. Copyright 2007 American Chemical Soceity.)
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content. Incomplete conversion to the cocrystal, resulting in a
mixture of cocrystals and excess starting material in the
product, is not desirable as it requires the use of addition
purification steps to yield a pure cocrystal product. Increasing
the grinding time can sometimes resolve this, but product
mixtures can also be an indication of nonstoichiometric
cocrystal formation. Dry grinding is typically attempted with
stoichiometric mixtures of target and coformer solids. This
requires formation of a stoichiometric cocrystal to consume all
available starting materials. Formation of a nonstoichiometric
cocrystal will thus lead to an excess of either remaining
material. Ideally, dry grinding should be completed using molar
equivalents and an excess of each starting material. This will
also facilitate discovery of alternative cocrystals if they exist for
a system.
Liquid assisted grinding involves the addition of a solvent,
typically in a very small amount, to the dry solids prior to the
initiation of milling. The solvent has a catalytic role in assisting
cocrystal formation and should persist for the duration of the
grinding process. More efficient cocrystal formation is
suggested for liquid assisted methods than with neat methods,
with a tendency for the cocrystal formation kinetics to increase
as the solvent added to the grinding media is increased,26 but
as yet this is inconclusive. The liquid component is thought to
accelerate reaction kinetics by wetting the solid surface. Liquid
assisted grinding has been reported in a number of different
formats. Trask et al. applied caffeine and maleic acid to make a
caf:ma cocrystal for the first time using neat and liquid assisted
grinding (LAG) methods. Their research suggested that a 1:1
or 2:1 caf:ma cocrystal could be manufactured after 30 and 60
min of grinding depending on the solvent selection.27 But in
2010, another method (ultrasound assisted solution cocrystal-
lization) was presented to form a purer cocrystal of caf:ma,
because the synthesized cocrystals by Trask et al. contained
impurities and were accompanied by different amounts of
caffeine.28 Benzoic acid cocrystals were formed by wetting an
equimolar mixture of benzoic acid and the carboxylic acid
coformer in a mortar with methanol and grinding it to
dryness.29 A total of 50 μL of nitromethane was added to an
equimolar mixture of caffeine and tetrafluorosuccinic acid with
grinding for 30 min at 30 Hz to form a 1:1 cocrystal; the same
method for a 2:1 mixture of caffeine and octafluoroadipic acid
yielded a 2:1 cocrystal.30 A total of 10 μL of ethanol or
nitromethane facilitated the formation of a 2:1 cocrystal from a
2:1 molar mixture of pterostilbene and piperazine, whereas 10
μL of toluene of 2-propanol facilitated the formation of a 1:1
cocrystal from a 1:1 molar mixture of pterostilbene and glutaric
acid.31 For generating highly water-soluble cocrystals of a
poorly soluble nutraceutical Hesperetin (HESP), the solvent
drop grinding cocrystallization method was applied. Chadha et
al. used different coformers such as picolinic acid (PICO),
nicotinamide (NICO), and caffeine (CAFF). Their research
has led to optimization of the pharmacokinetic properties by
improving the bioavailability. Also, the dissolution of prepared
cocrystals in an aqueous buffer showed that the hesperetin
concertation is around 4−5 times higher than that of the pure
one32 (Figure 2).
A wide range of carbamazepine cocrystals was generated
using solvent drop grinding and solvent evaporation in a
screening exercise by Weyna et al., and equivalent cocrystal hits
were achieved from either method.33 In general, there is no
clear logic proposed for solvent selection for liquid assisted
grinding experiments, with limited justification for solvent
choice provided in the existing literature.
2.1.2.1. Cocrystallization Mechanisms. It has been
suggested that the synthesis of new cocrystals is affected by
many variables, which are mostly affected by the nature of
solvent and the reactants. For example, the presence of
functional groups and the solubility of reactants in the solvent
in addition to many experimental conditions such as the
stoichiometric ratio of the coformer and API, temperature,
stirring, pH, and type of glassware are just a few of the effective
parameters.34 On the other hand, the rules of hydrogen
bonding, synthons, and graph sets could be helpful in
designing cocrystal systems. For instance, for an API
containing carboxylic acid, choosing coformers containing
acidic moieties or amides could increase the chance of
cocrystallization.35 However, there is no guarantee for cocrystal
formation. Thus, preparation of cocrystals is often a multistage
and empiric process.
As described above, many techniques are capable of
cocrystal synthesis. However, the lack of control over the
Figure 2. An example of equilibrium solubility (24 h) of hesperetin, HESP-PICO, HESP-NICO, and HESP-CAFF. (Reprinted with permission
from ref 32. Copyright 2017 American Chemical Society.)
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nucleation, crystallization, and phase evolution of the
cocrystals is still a significant scientific challenge.36 Mecha-
nochemical techniques are promising techniques for cocrystal
production from a green chemistry and affordable synthetic
pathway.37 For the first time in 1893, grinding was used as one
of the main techniques for cocrystal formation in order to
produce quinhydrone cocrystals from equimolar amounts of p-
benzoquinone and hydroquinone.38 Since then, many other
crystalline compounds have been formed through both
mechanisms of neat and wet grinding. Despite all the
technological improvements in the field, the underlying
mechanism(s) of cocrystal formation through these methods
has not been understood fully. Thus, many efforts have been
put into understanding the underlying mechanism of these
techniques. Fox has proposed the formation at very high
temperatures of around 1000 °C for a short period on the
order of milliseconds.39 Balaź ̌ has proposed the magma-plasma
model which considers the formation of transient plasma at
temperatures up to 10 000 °C to activate the reaction.37,40
However, no explanation is provided for the stability of the
coformer and API at these high temperatures.
Cocrystallization is not a single mechanism process, as Jones
and Frisč ̌ic ́ have mentioned,41 but rather a series of
mechanisms which include molecular diffusion, eutectic
formation,42 and cocrystallization through an amorphous
phase.43 The common point in these three mechanisms is
the presence of an intermediate bulk phase (gas, liquid, or
amorphous solid) with improved mobility and/or higher
energy of reactant molecules with respect to the starting
crystalline forms.
For each one of these mechanisms, there are examples in the
literature. It has been mentioned that molecular diffusion is
more likely in cases where one or both reactants have
significantly high vapor pressures in the solid state. The
availability of fresh surfaces enhances the molecular diffusion
on the reactant crystals.44 Additionally, it has been suggested
that mechanical force beaks down the intermolecular bonds of
the crystals of the reactant molecules.44 Figure 3 shows the
schematic of the cocrystal formation mechanism via grinding.
The solid and vapor diffusion are both significant in some cases
of cocrystallization, e.g., in cocrystals containing naphthalene.
However, in heavier aromatic hydrocarbons, surface diffusion
is a more effective mechanism of cocrystal formation.
In liquid phase assisted cocrystallization, the formation of
solid cocrystals is assisted by an intermediate liquid phase, e.g.,
when one of the reactants is liquid at ambient conditions.45−47
Eutectic formation in cocrystal synthesis is also an increasingly
significant mechanism in cocrystal formation.48 The cocrystal
formation at the interface of two colorless crystals of
diphenylamine and benzophenone was revealed by micro-
scopic observation, where the contact surface was converted
into liquid. Incorporating grinding with eutectic-mediated
cocrystallization enhances the process through two mecha-
nisms: first, increasing the fresh reactant surfaces for eutectic
formation and, second, improving the cocrystal nucleation in
the eutectic phase.41
In cases where there is no special mass transfer pathway (i.e.,
liquid or gas phase), cocrystallization can take place through
the formation of amorphous intermediates. This is possible in
cocrystallization of molecular solids with strong intermolecular
interactions (e.g., hydrogen bonds). Moreover, it has been
reported that grinding at temperatures below the glass
transition temperature of the reactants results in amorphous
phase formation; however, grinding at higher than that would
lead to metastable polymorphic forms.49
In liquid assisted grinding, the mechanism of cocrystal
formation has not been completely understood yet. In some
cases, it has been suggested that liquid just plays the role of
lubricant by providing a medium to facilitate the molecular
diffusion.41 Since the cocrystals formed after neat and liquid
assisted grinding are typically thermodynamically stable, the
low solvent fraction during liquid assisted grinding is of little
significance in controlling the outcome of the process. The
same rationale behind the liquid assisted grinding can be
applied to slurry cocrystallization as well. Moreover, the nature
of the liquid phase used in grinding can be significantly
influential during mechanochemical cocrystallization.50
The mentioned mechanisms are the ones mostly involved
with mechanochemical synthesis of cocrystals. As HME is a
mechanochemical method of processing, each one of these
mechanisms could be valid depending on the initial reactants,
mechanical forces, temperature, and liquids used during the
process.
2.1.3. Extrusion. Distinct from Hot Melt Extrusion (HME),
Twin Screw Extrusion (TSE) operates at temperatures below
the melting point of either starting material and takes place in a
distinct piece of equipmentan aptly named twin screw
extruder. This unit consists of two co-/counter-rotating screws
in a single barrel. Screw action provides simultaneous mixing
and movement of material along the length of the barrel.
Daurio et al. reported on the formation of four model
cocrystals using a 16 mm twin screw extruder with four
controllable temperature zones.51 Carbamazepine:saccharin,
theophylline:citric acid, caffeine:oxalic acid, and nicotinami-
de:cinnamic acid cocrystals were prepared by passing
stoichiometric blends of the dry powder of each starting
material through the extruder. The impact of temperature on
Figure 3. Schematic of cocrystal formation mechanism via
mechanochemical reaction (grinding). (Adapted with permission
from ref 41. Copyright 2009 American Chemical Society.)
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conversion to a cocrystal was specific to the cocrystal system
being studied, with no apparent temperature dependence for
cocrystals of carbamazepine:saccharin and a strong temper-
ature dependence for nicotinamide:cinnamic acid. In a separate
study, the same authors compared an AMG-157:saccharin
cocrystal prepared from TSE and solution crystallization.52
Cocrystals from TSE were shown to have improved surface
area, bulk density, and flow properties relative to those
produced from solution crystallization.
In another case study, carbamazepine-trans-cinnamic acid
cocrystals were extruded by both Single Screw Extrusion (SSE)
and TSE. According to the DSC and XRD results, less
crystallinity was observed for cocrystals which were manufac-
tured via a single screw extruder compared to a twin screw
extruder. Moreover, the dissolution rate of the TSE cocrystal
was higher than that of the SSE one.53
Medina et al. applied the TSE method for the first time to
manufacture cocrystals of caffeine and AMG 517. Their
research proved that TSE helps to have a highly efficient
mixing and close material packing, which leads to improvement
of surface contact between cocrystal components. Conse-
quently, cocrystal formation will be facilitated without adding
any solvent.54
Twin screw extrusion also was employed to manufacture
ibuprofen−nicotinamide cocrystals as a continuous process.
Off-line PXRD demonstrated the purity of the cocrystal to be
variable between 20% and 99% with different extrusion
conditions. This study showed that extrusion temperature,
screw configuration and screw rotation speed are the three
critical parameters to determine cocrystal purity. The optimum
situations to reach the purest ibuprofen−nicotinamide
cocrystal are the highest residence time (lowest speed) and
highest processing temperature with the most intensive mixing
screw.55
2.1.4. Hot Melt Extrusion. Hot melt extrusion (HME) is a
relatively recent addition to cocrystal preparation options. This
specialist technique combines simultaneous melting and
mixing of the target molecule and coformer via the use of a
heated screw extruder (Figure 4). Typically, the starting
materials are mixed in a molar ratio and fed to the heated
extruder. Melting occurs, facilitating intimate mixing of the
starting materials. The cocrystal nucleates directly in the melt,
and pure cocrystal extrudate is isolated from the extruder
continuously. The advantages of the method are elimination of
the use of organic solvents, fast operating times, increased
conversion relative to solution based methods, reduced waste,
and the technology lending itself well to continuous
pharmaceutical processing. Moradiya et al. described the
production of carbamazepine:cinnamic acid cocrystals using a
single screw and twin screw extruder.56 Cocrystals obtained
from the twin screw extruder displayed enhanced dissolution
properties relative to those obtained from the single screw/
solution based methods. Melt extrusion as a continuous
manufacturing technique was employed to produce indome-
thacin−saccharin cocrystals. Their studies proved that the
temperature profile, feed rate, and screw speed were the three
critical process parameters (CPP), which are needed for the
engineering of high quality cocrystals. Moreover, they showed
that temperature has no impact on the dissolution rate of
cocrystals.57 However, this is only valid in this case where the
samples have the same crystallinity based on Rietveld analysis.
It has been reported that in the case of deviation in the
crystalline quality by process temperature, the dissolution rate
will be affected subsequently. In contrast, the particle size of
cocrystals can have an influence on their dissolution
profile.58,59
Dhumal et al. manufactured the agglomerated cocrystal of
ibuprofen and nicotinamide by hot melt extrusion. They have
studied the effect of different processing parameters such as
screw speed, temperature profile, and screw configuration. It
was depicted that for cocrystallization to happen, the barrel
temperature must be above the eutectic point of physical
mixture. Also, in order to get the purer cocrystal, the highest
sheer screw configuration should be applied.60
Additionally, it was shown that incorporating the polymeric
matrix of xylitol in the manufacturing of the ibuprofen−
isonicotinamide cocrystal has a significant impact on the
torque of extrusion and the residence time. They studied the
effect of adding 10%, 30%, and 50% xylitol as a polymer. It has
been observed that with increasing the amount of xylitol, the
torque decreased and hence the residence time increased.61
Liu et al. also selected carbamazepine (CBZ) and
nicotinamide (NIC) as a model drug and coformer,
respectively, to manufacture an amorphous CBZ-NIC cocrystal
solid dispersion via the HME method. The main scope of their
study was to show cocrystallization as a considerable approach
to prevent thermal degradation of heat sensitive drugs during
HME. First, they proved that CBZ and NIC could in situ
cocrystallize in PVP/VA during the process of heating in hot
melt extrusion. The newly formed cocrystal completely melted
around 160 °C. This temperature is 30 °C lower than the Tm
of CBZ. Hence, the CBZ-NIC-polymer solid dispersion could
be successfully prepared while preserving heat sensitive API
from thermal degradation via HME.62
2.1.5. High Shear Wet Granulation. Typically employed for
drug product formulation, high shear wet granulation has been
investigated as a route to cocrystal preparation. This technique
involves the agglomeration of powder particles via a liquid
medium in the presence of a binder. Technically, the
procedure is carried out in a high shear granulator, which
Figure 4. Schematic representation of a typical HME instrument.
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imparts shear on the powder mixture through impellers and
choppers. The mechanism of cocrystal formation by high shear
granulation is not exactly known but suspected to be either
similar to liquid assisted grinding or slurry transformation.
Granules containing a 1:1 piracetam:tartaric acid cocrystal
were successfully produced from a mixture of piracetam,
tartaric acid, and a variety of excipients in the presence of water
using a Bohle mini granulator.63 The extent of cocrystal
formation was impacted by the volume of granulation liquid
used, impeller speed, and the excipient mixture used, with 95%
conversion achieved within 5 min.
In another case study, Slad́kova ́ et al. studied the vabradine
hydrochloride (S)-mandelic acid 1:1 cocrystal (IClSM) and
the effect of adding two different granulation liquids. First,
lactose monohydrate was added as a common formulation
filter to the mixture of API and coformer. Then, water and
ethanol were applied to granulate it. The results showed that
no cocrystal formation was observed when water was applied
for granulation in the presence of lactose monohydrate, while
by adding ethanol the cocrystal was formed and PXRD
depicted the cocrystal characteristic peaks.64
2.2. Solution Based Methods. A variety of methods exist
to cocrystallize from solution, and each will be discussed in the
subsequent section. At the outset, it is worthwhile considering
some universal solution crystallization concepts. The driving
force for crystallization is supersaturation, the difference
between the actual experimental concentration and the
reported solubility concentration at that temperature in that
solvent. With a cocrystal system, there are two concentrations
to consider, that of the target molecule and that of the
coformer. The concentrations of both relative to the solubility
of the cocrystal (most accurately expressed in terms of target
molecule and coformer) dictate the supersaturation for
cocrystallization. A eutectic point will exist where at one
fixed solution concentration, a mixture of cocrystal and the
target molecule is the stable solid phase for the system; a
second eutectic point exists for a mixture of the cocrystal and
coformer. The eutectics represent solution minima where the
solvent content is at its lowest value, meaning solubility is at its
highest value. The cocrystal will only be stable, less soluble
than target molecule or coformer, at concentrations lying
between the eutectic points. Knowledge of this concentration
range, termed the cocrystal operating range, is key to designing
a successful solution cocrystallization. Operation outside of this
range can fail to yield a cocrystal or can yield a cocrystal/target
molecule or cocrystal/coformer mixture in the solid phase. The
solubility of a cocrystal system is most accurately represented
in a ternary phase diagram (TPD). This triangular diagram
illustrates the solubility of the solid phases in a given solvent at
a fixed temperature and pressure and also identifies regions of
stability for different solid phases in the system.65,66
Figure 5 shows the typical ternary phase diagrams which
describe the three-phase behavior of a multicomponent
system: API, coformer, cocrystal, and solvent. It is also able
to predict the pathway of cocrystal formation.
Crystallization from solution is an established unit operation
for single component crystallizations, and one would imagine
that this technique has the greatest industrial potential for up-
scaling cocrystal preparation without moving toward the
specialist techniques.
Screening cocrystal systems via solution cocrystallization in
combination with grinding approaches can significantly
enhance the exploration of a variety of cocrystal systems. As
an example, the potential of cocrystal formation of caffeine
with dicarboxylic acids was investigated by the solution
cocrystallization of caffeine/L-malic acid.68
2.2.1. Evaporative Cocrystallization. Evaporative cocrystal-
lization is a common method of generating cocrystals, typically
employed for generating single crystal cocrystals suitable for
diffraction studies to elucidate cocrystal structure. The
technique involves the nucleation and growth of a cocrystal
from a solution of both coformers in a solvent, with
supersaturation provided by removal of the solvent from the
solution via evaporation. Individual cocrystals, or the bulk
crystal sample, should be harvested before the solution
evaporates to dryness to ensure recovery of a clean crystal(s).
A slow rate of evaporation is usually desired so as to ensure
formation of a small number of larger crystals as opposed to a
high number of smaller crystals. As crystal structure
identification is a necessary step in the discovery of new
cocrystal forms, evaporative cocrystallization is evident in the
majority of cocrystal related research papers, and there are
countless examples of it in the literature. It should be noted
that identification of the crystal structure is a necessity for
defining whether the obtained crystal is a cocrystal, salt,
hydrate, or any other polymorphic form of the API or
coformer. A classic example is provided by Basavoju et al. in
the description of the generation of single crystals of a
norflaxin-isonicotinamide cocrystal from chloroform: 0.1 mmol
of norflaxin and 0.1 mmol of isonicotinamide are dissolved in 8
mL of chloroform. The chloroform was subsequently allowed
to evaporate at room temperature, yielding rod shaped single
crystals of a 1:1 norfloxacin:isonicotinamide cocrystal.10
Another example of making cocrystals with the solvent
evaporation method was shown by Chow et al. for
ibuprofen−nicotinamide and flurbiprofen−nicotinamide coc-
rystals, which exhibited higher intrinsic dissolution rates
compared to the corresponding profens. Moreover, the
synthesized cocrystals presented higher tabletability and less
absorbed humidity compared to the individual precursors.69
This method is typical in that most evaporative cocrystal-
lizations are performed in stoichiometric solutions, typically a
1:1 molar ratio of precursors. However, this is not
recommended as it tends to only yield stoichiometric
cocrystals and will not identify cocrystals with unequal API/
coformer ratios when they do exist for a cocrystal system.
Ideally, evaporative cocrystallization should be performed from
three solutions: 1:1 stoichiometric solution, a solution where
Figure 5. Schematic representation of isothermal ternary phase
diagram. (a) Similar solubilities between API and coformer (1 and 2)
in solvent S and (b) different solubilities of 1 and 2 in S. Region A,
component 1 and solvent; B, component 1 + cocrystal; C, cocrystal;
D, component 2 + cocrystal; E, component 2 and solvent; F, solution.
(Modified from ref 67. Copyright 2013 Cell Press.)
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the coformer is in excess, and a solution where the target
molecule is in excess.70 Not only will this increase the
probability of obtaining a cocrystal, it will also identify
cocrystals with unequal API/coformer ratios where they are
possible. In studies to date, there is limited attention given to
the role of the solvent in evaporative cocrystallization.
In theory, there is no reason why evaporative cocrystalliza-
tion could not be used at larger scales to produce bulk amounts
of cocrystal products. In this case, single crystal formation
would not be required, and the cocrystallization could be
optimized the same as any crystallization process. At lab scale,
evaporative cocrystallization tends to occur from very dilute
solutions. This is oftentimes due to a lack of solubility
information on the precursor molecules in the solvent but can
also be a purposeful attempt to reduce the rate of
supersaturation to promote the formation of larger crystals.
Optimization of these starting concentrations and process
conditions could design an efficient large scale evaporative
cocrystallization. In practice this could be difficult to operate
and control, possibly leading to the preferred selection of
alternative cocrystallization routes at larger scales.
Depending on the volatility of the solvent, evaporative
cocrystallization can be very slowevaporation times of up to
six months have been reported.71 While slow evaporation is
desirable to generate single crystals, extended evaporation
times are a hindrance to progress. Various techniques can be
used to accelerate the rate of evaporation during evaporative
cocrystallization, with the aim of decreasing the process time
required to yield cocrystals. Elevated temperature has been
employed, where evaporation of methanol from a stoichio-
metric solution of ezetimibe and methyl paraben in methanol
was conducted at 35 °C using a water bath. Evaporation (to
dryness) of an unspecified organic solvent from a solution of
curcumin and phloroglucinol was achieved under a vacuum
using a rotary evaporator at 60 °C to generate a powder
cocrystal sample.72
2.2.2. Cooling Crystallization. A designed seeded cooling
crystallization was used to prepare cocrystals of carbamazepi-
ne:nicotinamide from ethanol, in an effort to establish a
scalable solution cocrystallization strategy.73 Solvent selection,
identification of the thermodynamically stable cocrystal
operating range, and desupersaturation kinetics were consid-
ered in design of the process, which was demonstrated at 1 L
scale with 90% yield and 14 L kg−1 throughout. A similar
approach was taken by Holaň et al. in the preparation of
agomelatine:citric acid cocrystals, and the impact of cooling
rate and seed amount on the crystal size distribution in the
final product was assessed.74
2.2.3. Reaction Cocrystallization. Reaction cocrystallization
was used to produce cocrystals of carbamazepine:saccharin by
combining individual feed solutions of either of the starting
materials.75 The method was informed by the ternary phase
diagram and illustrated a robust operating range for cocrystal
formation and demonstrated the expected relationship
between supersaturation and induction time. Formation of a
carbamazepine:nicotinamide cocrystal was also done by
reaction cocrystallization under ambient conditions.76
2.2.4. Isothermal Slurry Conversion. This technique
involves the suspension of the target molecule and coformer,
usually in a fixed molar ratio, in a solvent with the solid fraction
always remaining in excess. In practical terms, the technique
can also operate by adding the target molecule to a solution or
suspension of coformer in solvent. While this is a solution
based method, it does not require generation of a clear (fully
dissolved) starting solution, as is the case with the previous
methods described above.
The rate at which slurry conversion occurs will differ based
on the solubility driving force, the relative concentrations of
the target molecule and coformer, and the nucleation and
growth kinetics of the system. There have been limited kinetic
accounts of isothermal slurry conversion for any cocrystal
system. Zhang et al. investigated the transformation time for
theophylline to convert to a 1:1 glutaric acid cocrystal. Times
ranging from 15 min to 5 h were recorded for complete
conversion depending on solution concentration and solvent
selection. It was proposed that the transformation time to
cocrystal decreases with increasing solubility in a given solvent.
Jayasankar et al. directly investigated the impact of coformer
concentration on the outcome of slurry conversion for the
carbamazepine:4-aminobenzoic acid cocrystal. This system
forms two cocrystals, a 1:1 and a 2:1 form. Equilibration of
excess carbamazepine at a low (0.1 M) 4-aminobenzoic acid
(4-ABA) concentration for an unspecified equilibration time
yielded no cocrystal; pure carbamazepine persisted. The same
experiment at 0.6 M 4-ABA yielded the 2:1 cocrystal, and with
excess 4-ABA present, the 1:1 cocrystal was formed. This
relates to the position of the experimental composition on the
ternary phase diagram, again reflecting the importance of a
well-defined ternary phase diagram for a cocrystal system. The
yield and productivity of isothermal slurry conversion can vary
widely based on the operating conditions and concentrations
and can also be optimized through use of the TPD.77 Cheney
et al. showed that 96% cocrystal yield was achieved for a slurry
conversion of meloxicam with aspirin in 3 mL of tetrahy-
drofuran (THF) at ambient conditions overnight.78 Croker
and Rasmuson demonstrated the purity and process
efficiencies that can be achieved with isothermal slurry
conversion for the toluenesulphonamide:triphenylphosphine
oxide cocrystal system.79 Although the slurry conversion
method typically requires a greater amount of starting materials
and will incur some material loss due to residual solubility in
the solvent, it is considered one of the most promising
screening techniques due to its high efficiency.
2.3. Supercritical Fluid Methods. Cocrystals have been
successfully produced using supercritical fluid technology,
primarily with the use of supercritical carbon dioxide (CO2),
by three different approaches which focus on distinct
supercritical CO2 properties: solvent, antisolvent, and atom-
ization enhancement.80
2.3.1. Cocrystallization with Supercritical Solvent. The
Cocrystallization with Supercritical Solvent (CSS) technique
uses the solvent power of supercritical CO2 to suspend the API
and the coformer as a slurry in liquid or supercritical CO2,
avoiding the use of toxic organic solvents.81 By controlling the
thermodynamic conditions of CO2 (e.g., temperature,
pressure), it is possible to fine-tune its density and solvent
power, which provides control over the cocrystallization
between cocrystal components. Subra-Paternault et al. have
compared the cocrystallization outcome of distinct APIs (e.g.,
indomethacin, theophylline, carbamazepine, caffeine, sulfame-
thazine, and acetylsalicylic acid) with saccharin in liquid and
supercritical CO2.
82 Those authors have suggested that despite
the usual low solubility of most cocrystal components (API
and coformer) in CO2, cocrystallization is mediated by their
dissolution in it. In particular, they have observed that by
increasing the concentration of the cocrystal components in
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the CO2 phase, the cocrystallization rate is increased. In
addition to this, stirring of the cocrystal components in the
CO2 slurry promotes intense mass transfer by convection,
which was found to be paramount to achieving complete
cocrystallization and obtaining cocrystalline products with no
traces of their starting components.
2.3.2. Rapid Expansion of Supercritical Solvents. The
Rapid Expansion of Supercritical Solvents (RESS) technique
consists of the saturation of the supercritical fluid (supercritical
CO2) with a solid substrate (API and coformer in the case of
producing cocrystals) prior to the depressurization of the CO2
phase through a nozzle into a drying chamber at atmospheric
pressure. Müllers et al. have used this process to produce
microparticles of ibuprofen-nicotinamide cocrystals.83 The
main drawback of this technique is that the starting
components (API and coformer) have to be soluble in
supercritical CO2, as unfortunately most pharmaceutical
molecules have a very low solubility in it.
2.3.3. Supercritical Antisolvent Cocrystallization. Using
supercritical CO2 as an antisolvent for cocrystallization works
on the principle that solubility of API and the coformer is
reduced in supercritical CO2, allowing them to precipitate
together in a cocrystalline structure. This approach has the
potential to control the polymorphic form of the API or
cocrystals produced.82,84,85 It has been used for the production
of cocrystals by two distinct techniques: (1) a batch gas
antisolvent (GAS) process which involves saturating a solution
containing the dissolved API and coformer inside a high
pressure vessel with CO2 until cocrystallization occurs
82,84 and
(2) a semicontinuous supercritical antisolvent (SAS) process
which involves forcing a solution containing the dissolved API
and coformer molecules through a nozzle into a high pressure
vessel containing supercritical CO2.
80 In both techniques, the
CO2 dissolves in the solvent simultaneously expanding its
volume and reducing it solubilizing ability, ultimately resulting
in precipitation. Ober and Gupta demonstrated GAS in the
formation of itraconazole-succinic acid cocrystals and
compared the properties of the cocrystals thus formed, to
those formed from conventional solution antisolvent cocrystal-
lization.84,86 Cocrystal structure and habit were equivalent
from both preparation methods, but agglomeration properties
were modified. GAS resulted in the formation of rosette type
agglomerates which demonstrated an enhanced dissolution
profile relative to the spherulite agglomerates formed from
liquid antisolvent. Padrela et al. demonstrated the SAS process
for the formation of micron-sized needle and block-shaped
particles of indomethacin-saccharin cocrystals.80 Other authors
have used the SAS process to produce naproxen-nicotinamide
and diflunisal-nicotinamide cocrystals and have observed the
CO2/solution flow ratio to have paramount importance in the
production of cocrystal-pure powders.86,87
Figure 6. Schematic diagram of the SEA apparatus. (1) CO2 cylinder; (2) liquid solution flask; (3) temperature controlled CO2 storage cylinder;
(4) precipitator; (5) filter; (6) solvent trap; (7) detail of the nozzle cap. P, T, F: instruments for, respectively, pressure, temperature, and flow
measurements. Tc is for temperature control and measurement (Reprinted with permission from ref 88. Copyright 2010 Elsevier.)
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2.3.4. Supercritical CO2-Assisted Spray Drying. Using
supercritical CO2 as an atomization enhancer is based on the
supercritical fluids’ ability to enhance the breakup of liquid jets
into fine droplets when depressurized simultaneously with
liquid solutions (Figure 6). This is a single-step process which
consists of spraying a solution containing the dissolved starting
cocrystal components through a nozzle with supercritical CO2
into a drying chamber at atmospheric pressure. Padrela et al.
have used the Supercritical Enhanced Atomization (SEA)
technique to produce micro- to nanosized cocrystals of
theophylline with several coformers and fine-tune the cocrystal
particles’ morphology and dissolution properties.88,89 Interest-
ingly, this technique was also successfully used to generate
microcomposites of theophylline-saccharin cocrystals dispersed
in hydrogenated palm oil as a controlled release formulation.90
The above methods represent the majority of standard
approaches to cocrystal formation and are summarized in
Table 1. Recently emerging preparation methods, which are
relatively uncommon, are reviewed in section 2.4.
2.4. Miscellaneous Cocrystal Preparation. 2.4.1. Laser
Irradiation. This method consists of using a high-power CO2
laser to irradiate powder blends of cocrystal formers and
induce their recrystallization to a cocrystal structure.
Titapiwatanakun et al. have used this method to produce
caffeine cocrystals with oxalic acid and malonic acid.91
Interestingly, these authors have found that the cocrystal
formers need to sublime to a considerable extent for the
cocrystallization to take place, which indicated that the
mechanism of the molecular rearrangement between API and
coformer molecules and the nucleation of the cocrystal is likely
to take place in the vapor phase.
2.4.2. Electrochemically Induced Cocrystallization. Ur-
banus et al. demonstrated the potential of using cocrystalliza-
tion combined with electrochemistry for in situ product
removal of carboxylic acids.92 Proof-of-principle was estab-
lished using a cinnamic acid and 3-nitrobenzamide cocrystal
system. This work showed that electrochemistry can be used to
locally shift the pH to obtain neutral carboxylic acids and
generate a local driving force for cocrystallization.
2.4.3. Resonant Acoustic Mixing. Resonant acoustic mixing
has been used to mix the target molecule and coformer in the
presence of a liquid to form a cocrystal in the absence of any
grinding media. In this method, mechanical energy is
transferred acoustically into a wetted powder mixture,
encouraging intimate mixing of the components. A range of
carbamazepine cocrystals were successfully produced using a
labRAM resonant acoustic mixer operating at 80−100G and 60
Hz. The cocrystal products were isolated at a range of
laboratory scales, 100 mg and 1.5 and 22 g, and the technology
appeared amenable to scale-up.93
2.4.4. Spray Drying. Spray drying is a continuous single-step
method of transformation of liquids (solutions, suspensions,
slurries) to solid powders.94−96 It is advantageous due to its
continuous, highly controllable, and fast process. Although
spray drying has been widely used in formulating amorphous
solid dispersions because of the fast solidification process, it
has also been employed in synthesis of cocrystals.97 Alhalaweh
and Velaga spray dried several combinations of API-coformer
with the aim of cocrystallization. They claim that cocrystalliza-
tion has been observed in highly supersaturated regions of the
drug due to the rapid solvent evaporation, presence of the
coformer, or interaction between the drug and coformer in
liquid form.98 Another application of spray drying to generate
pharmaceutical cocrystals was done to prepare the carbama-
zepine−nicotinamide cocrystal (CNC; 1:1). Also, it was
proved that TPD can be used for the formation of cocrystals
by industrially feasible spray drying methods.99 Spray drying
can also be used to produce cocrystals embedded in an
excipient matrix with enhanced rheological properties. Walsh
et al. have demonstrated the production of cocrystals
(sulfadimidine as the poorly soluble model API and 4-
aminosalicylic acid as the coformer) by spray drying in the
presence of a third component (excipient matrix).100 It was
found that a larger difference in HSP (Hansen Solubility
Parameters) between the cocrystal components and the
excipient promotes cocrystal formation during spray drying
in the presence of a carrier excipient, as the cocrystal
components will not be miscible with the excipient. This
leads to the cocrystal components (API and coformer)
remaining phase separated from the excipient but still
interacting/cocrystallizing with each other, generating a
cocrystal phase embedded in excipient matrix. The compaction
properties of these cospray dried (sulfadimidine and 4-
aminosalicylic acid with excipient) cocrystal systems were
notably improved compared to the spray dried (sulfadimidine
and 4-aminosalicylic acid without excipient) cocrystals, due to
less sticking characteristics.
2.4.5. Freeze-Drying. Freeze-drying, technically known as
lyophilization, has been mostly used as a processing technique
to preserve a wide variety of products, which include food and
pharmaceuticals. This process works by freezing the material
and then reducing the surrounding pressure to allow the frozen
water in the material to sublime directly from the solid phase
to the gas phase. It has also has been demonstrated recently to
be a feasible method for the preparation of new solid forms of
cocrystal systems.101 Eddleston et al. prepared a new form of
the theophylline:oxalic acid cocrystal using freeze-drying.
Cocrystallization takes place via an amorphous phase that is
generated as solvent sublimes during the freeze-drying process.
2.4.6. Electrospray Technology. Electrospraying is a process
of simultaneous droplet generation and charging by means of
an electric field. In this process, a solution containing the
dissolved substances flows out from a capillary nozzle, which is
maintained at high potential, through an electric field, which
causes elongation of the solution droplets to form a jet. The
solution jet is dried, and the generated particles are collected
on a charged powder collector. Patil et al. demonstrated the
potential of this process to generate cocrystals of carbamaze-
pine and itraconazole with different coformers.102
3. COCRYSTAL APPLICATION AREAS
Cocrystal formation results in a new crystal structure, which is
entirely independent from any of the starting materials. This
new crystal structure imparts a new set of physical properties,
also independent of and indifferent to the physical properties
of any of the starting materials. Currently, the crystal structure
and resulting physical properties of a cocrystal cannot be
predicted from any property of the starting materials. As a
result of potential physical property improvements, cocrystal
applications are many and continue to grow.
3.1. Solubility. By far the most prolific utility of cocrystals
to date has been to improve the solubility of the starting
material, particularly when that starting material is an active
pharmaceutical ingredient. Low aqueous solubility is a barrier
to satisfactory drug delivery and, as such, often prevents a
medicine from being fit for its purpose. Inherently, a cocrystal
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will have a different solubility than that of either of the starting
materials due to the altered underlying crystal structure. The
solubility alteration can be in either direction. Enhanced
solubility is desirable, as it will improve the bioavailability of
the drug, but excessive enhancement can be problematic as it
can lead to undesirable precipitation of the starting material
due to the generation of a supersaturated solution.23 This has
been characterized for cocrystal materials as a “spring and
parachute” effect103 (Figure 7).
Zheng et al. reported improved solubility of resveratol upon
cocrystallization with 4-aminobenzaamide and isoniazid.104 Hu
et al. demonstrated an increase in aqueous solubility from 7.5
mg/L febuxostat to 571 mg/L for a febuxostate:arginine
cocrystal,105 showcasing the potential physical property
modification that can be achieved with cocrystals. Perlovich
and coauthors demonstrated that cocrystals can improve or
reduce solubility as a function of the coformer for 4
aminosalicyclic acid.106 Cocrystallization with isoniazid,
caffeine, pyranzinamide, nicotinamide, and isonicotinamide
resulted in cocrystals (sometimes hydrated) which increased
aqueous solubility at pH 2.0 by at least a factor of 2, while
cocrystallization with theophylline was found to reduce the
solubility by half in the same solution. This was due to partial
cocrystal disintegration back to original starting materials in
solution.
There are many other accounts of improved solubility upon
cocrystal formation available in the literature, but it is worth
recalling the true nature of solubility as we consider the
cocrystal solubility impact. Solubility is a thermodynamic
measure of the amount of a solute that can be contained in a
given volume of solvent at fixed conditions (temperature and
pressure). The presence of impurities in the solvent or solute
will affect solubility measurements. In the case of cocrystals,
the coformer can be considered as an impurity and therefore
be expected to alter the solubility of the starting material. This
is often not accounted for in reported solubility measurements
where cocrystal solubility is compared to the starting material
solubility in the pure solvent. To compare like with like, it is
more accurate to compare the solubility of the cocrystal with
the solubility recorded for the equivalent physical mixture, or
at least in the presence of some known concentration of the
coformer. The expected impact of the coformer on cocrystal
solubility is lacking in the majority of published accounts. An
extensive study by Pastore et al. addressed this exact issue in
2015 by comparing the solubility, dissolution, and permeability
characteristics of raw carbamazepine with three of its cocrystals
(vanillin, succinc acid, and nitropyridine N-oxide) and their
respective physical mixtures. The authors concluded that the
physical mixtures were distinct from the cocrystal material
verifying the pharmacological impact of cocrystal materials.107
The collective work of Rodriguez-Hornedo has also extensively
addressed cocrystal solubility and has proposed the concept of
a solubility product, Ksp, which takes into account the relative
concentrations of both cocrystal formers during cocrystal
dissociation in a solvent.108
= [ ] [ ]K A Ba bsp
when activity coefficients are taken as unity; superscripts refer
to the stoichiometric number of molecules of a/b in the
cocrystal. The solubility product reflects the strength of
cocrystal solid state interactions of the drug and ligand relative
to interactions with the solvent and is also correlated to
solubility, with a higher Ksp indictaing higher cocrystal
solubility.109
3.2. Bioavailability. Cocrystals bear the potential to
enhance the delivery and clinical performance of drug products
by modulating drug solubility, pharmacokinetics, and bioavail-
ability. Particularly, using cocrystals to improve oral drug
absorption of BCS class II and IV drugs has been a strong
focus of several case studies published in the literature. Stanton
et al. have compared the improvement on the solubility and
pharmacokinetics of AMG 517, a potent and selective transient
receptor potential vanilliod 1 (TRPV1) antagonist, when
cocrystallizing this drug with carboxylic acid (cinnamic acid
and benzoic acid and amide coformers (cinnamamide and
benzamide)).110 All four AMG517 cocrystals showed faster
intrinsic and powder dissolution rates in fasted simulated
intestinal fluid than the free base of AMG 517. The results on
the pharmacokinetics showed a 2.4- to 7.1-fold increase in the
area under the concentration−time curve in rat PK
investigations, which highlights the improvement in bioavail-
ability of AMG 517 when in a cocrystalline form. Other studies
have demonstrated the efficiency of cocrystallization in
improving the solubility and bioavailability of poorly soluble
APIs such as indomethacin,111 baicalein,112and quercetin.113
Interestingly, polymers and other excipients can provide a
huge contribution to improving the bioavailability of cocrystals
by acting as crystallization inhibitors and prolonging the
supersaturation concentration of cocrystals during dissolution.
This approach is particularly important in situations where the
cocrystal transforms rapidly to a low-solubility form of the drug
and is unable to maintain desired solubility levels necessary to
ensure optimal absorption. Childs et al. improved the solubility
and bioavailability of a danazol:vanillin cocrystal by using an
appropriate formulation containing a combination of cocrystal,
a solubilizer (1% vitamin E-TPGS (TPGS)), and a
precipitation inhibitor (2% Klucel LF Pharm Hydroxypropyl-
Figure 7. Spring and parachute concept to achieve high apparent
solubility for insoluble drugs. (1) The crystalline (stable) form has
low solubility. (2) A short-lived metastable species (i.e., amorphous
phase) shows peak solubility but quickly drops (within minutes to an
hour) to the low solubility of the crystalline form. (3) Highly soluble
drug forms are maintained for a long enough time (usually hours) in
the metastable zone. (Reprinted with permission from ref 103.
Copyright 2016 Elsevier.)
Crystal Growth & Design Review
DOI: 10.1021/acs.cgd.8b00933
Cryst. Growth Des. XXXX, XXX, XXX−XXX
K
cellulose).114 This formulation resulted in a high improvement
in the bioavailability of the cocrystal by over 10 times
compared to the poorly soluble danazol polymorph. Another
example of cocrystals that undergo rapid precipitation during
dissolution and form a dihydrate form of the parent drug in
aqueous media is dihydromyricetin-caffeine and dihydromyr-
icetin-urea cocrystals. Wang et al. have improved the
bioavailability of these cocrystals by inhibiting the precipitation
of dihydromyricetin using polyvinylpyrrolidone K30 as a
crystallization inhibitor.115 Approximately 5-fold enhancement
in oral bioavailability of dihydromyricetin was achieved when
both cocrystals were dosed with 2.0 mg/mL polyvinylpyrro-
lidone K30 solution compared to dihydromyricetin dihydrate
suspended in a similar same dissolution medium.
3.3. Controlled Release. Cocrystallization provides an
opportunistic approach to modulate the physicochemical
properties of pharmaceutical drugs, which include solubility
and dissolution rate. Particularly, depending on the coformer
that cocrystallizes with the API, the dissolution rate of the API
in water or a buffer solution can be increased or decreased over
time. Carbamazepine−cinnamic acid cocrystals synthesized by
solvent evaporation showed a higher dissolution rate,
solubility, and stability in water compared to carbamazepine.116
Arenas-Garcia et al. produced several cocrystals of acetazola-
mide (ACZ) with enhanced intrinsic dissolution rates when
compared to pure ACZ in a medium simulating physiological
conditions (HCl 0.01N, pH 2.0).117 The cocrystals which
provided the largest dissolution rates were those which showed
the poorest solid-state stability in the same medium by initially
undergoing solvent mediated phase transformation.
Cocrystals also bear the potential to reduce the dissolution
rate of the original APIs. Chen et al. used the cocrystallization
approach to sustain the dissolution behavior of ribavirin, a
water-soluble antiviral drug.118 These authors demonstrated
that the release rate of ribavirin can be manipulated over a
wide range by the formation of cocrystals, which may
subsequently help lower its peak-to-trough fluctuation in
plasma concentrations.
Padrela et al. used a supercritical fluid enhanced atomization
(SEA) process, which is a nanospray drying method that uses
the atomization potential of supercritical CO2 to disperse and
dry a drug solution through a coaxial nozzle, to produce micro-
to nanosized cocrystals of theophylline with several co-
formers.119 The authors found that the solubility of each
coformer in the dissolution medium (phosphate-buffered
saline, pH 7.4 at 25◦C) could determine the dissolving rate
behavior of the produced cocrystals. Consequently, low-soluble
coformers provided TPL cocrystals with slow-dissolving rates,
while highly soluble coformers provided faster-dissolving TPL
cocrystals.
Tiago et al. reduced the dissolution behavior and improved
the solid state stability of theophylline by generating cocrystals
of this drug with saccharin dispersed in a lipid using the SEA
process.90 The dissolution of theophylline was further
improved when theophylline-saccharin cocrystals (TPL-SAC)
were formed and dispersed in hydrogenated palm oil (HPO)
during the SEA processing. The SEA process provided
improvement of TPL stability and delivery by single-step
micronization, cocrystallization, and encapsulation. Depending
on the ratio of TPL-SAC to HPO, the dissolution rate of TPL
could be further sustained over time with increasing
proportions of HPO in the TPL-SAC-HPO microcomposites.
In addition to this, the TPL-SAC-HPO microcomposite
particles were able to attenuate the TPL burst effect.
The presence of polymers in the dissolution media might
also impact the supersaturation level and dissolution rate of
cocrystals. Guo et al. have studied the impact that the presence
of different polymers (polyethylene glycol (PEG), polyvinyl-
pyrrolidone (PVP), and polyvinylpyrrolidone/vinyl acetate
(PVP-VA)), which have been predissolved in a solution
medium, has on the dissolution behavior of flufenamic acid−
theophylline (FFA-TPL) and flufenamic acid−nicotinamide
(FFA-NCT) cocrystals.120 It was demonstrated that by
controlling the dissolution environment with the presence of
certain polymers, such as PVP or PVP-VA, which can interact
with the crystal surface to alter its dissolution properties, the
solubility and dissolution rates of FFA-TPL and FFA-NIC
cocrystals is significantly improved.
3.4. Multidrug Cocrystals. Combining multiple active
pharmaceutical ingredients (APIs) into one unit dose has
become a popular trend in the drug formulation industry. The
need to target multiple receptors for effective treatment of
complex disorders such as HIV/AIDS, cancer, and diabetes in
addition to the increasing demand for facilitating the reduction
of drug manufacturing costs are the two main reasons for this
growing trend. Salts, mesoporous complexes, coamorphous
systems, and cocrystals are systems which have been used for
combining multiple APIs in a single delivery system.121
Multidrug cocrystals (MDCs) are advantageous compared to
coamorphous systems in terms of their enhanced stability and
in terms of their reduced payload compared to the mesoporous
and cyclodextrin complexes. Thipparaboina et al. defined the
MDCs as “dissociable solid crystalline supramolecular
complexes comprising two or more therapeutically effective
components in a stoichiometric ratio within the same crystal
lattice, wherein the components may predominantly interact
via nonionic interactions and rarely through hybrid inter-
actions (a combination of ionic and nonionic interactions
involving partial proton transfer and hydrogen bonding) with
or without the presence of solvate molecules.”122−124
MDC could offer potential advantages compared to the pure
drug components, such as enhanced solubility and dissolution
of at least one of the components,125,126 enhanced bioavail-
ability,78 improved stability of unstable APIs via intermolecular
interactions,127,128 and increased mechanical strength and
flowability. MDC formulation of ethenzamide and gentinsic
acid was reported with an improved intrinsic dissolution rate.
Meloxicam and aspirin containing MDC was developed with a
12-times decrease in the time to reach the therapeutic
concentrations and 4-fold bioavailibity enhancement. An
extensive list of MDCs can be found elsewhere.129 On the
other hand, there are examples of MDCs with lower intrinsic
dissolution rates compared to pure APIs. Kaur et al. reported
the MDC of two anticonvulsants, lamotrigine and phenobarbi-
tal. The two molecules form heterodimers through hydrogen
binding. Dissolution studies in phosphate buffer (pH 7.2)
revealed the decreased dissolution rate of cocrystals in the
order of pure phenobarbital > pure lamotrigine > cocrystal.130
So far, no computational approach has been developed for
predicting and/or screening of MDC formulations. Thus,
prediction and screening of the potential MDC formulations
mostly follows the knowledge-based approach, which includes
hydrogen-bond tendency, pKa studies, use of synthons, and
molecular descriptors. Synthon engineering is all about
studying the structural units within the supermolecules that
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are capable of forming intermolecular interactions. Carboxylic
acid dimers, acid-pyridine, phenol-pyridine, and phenol-
carboxylic acid are the most frequently seen synthons.131
Moreover, the Cambridge Structural Database (CSD) could be
used to screen the possible hydrogen bondings and synthon
competitions.132
pKa was used as a simple tool for the prediction of cocrystal
formation. It was shown that generally a difference between
pKa base and pKa acid (ΔpKa) > 3 leads to the formation of
salts, while ΔpKa < 0 results in cocrystal formation. More
modifications have been made to the use of ΔpKa as a measure
of cocrystal formation by Cruz Cabeza et al., where they
studied 6465 crystalline structures in CSD and validated and
measured their ΔpKa. They found a linear relationship
between the possibility of proton transfer between acid−base
pairs and the ΔpKa.133
The main techniques of cocrystal synthesis have been used
for preparing MDCs as well. These techniques include
distillation, solvent evaporation, neat and liquid-assisted
grinding, slurry reaction, melting, and cooling crystallization.
Scale-up techniques such as spray-drying,99 hot melt
extrusion,134 twin screw extrusion,51 and high shear gran-
ulation63 have been used for scale-up production of cocrystals.
The MDC formulation approach has been evolved a lot
from exploring different combinations of APIs, yet more efforts
are required for selection for therapeutically relevant APIs that
could be beneficial to the patients and pharmaceutical industry.
Moreover, more efforts are required in terms of predictive
modeling of the cocrystallization process of two APIs.
3.5. Mechanical Properties Enhancement. Tableting is
the most popular pharmaceutical dosage form due to its
numerous technical and economic advantages. Low manufac-
turing cost; high production throughput; and ease of
consumption, storage, and handling are some of these
benefits.135 However, several deficiencies caused by poor
flowability and mechanical properties have always been a
difficulty along the way to successful tablet production.
Several strategies have been employed to address these
issues during the formulating process of APIs. Adding silicon
dioxide for increasing mechanical strength of tablets and
magnesium stearate for improved flowability are some of these
techniques. Cocrystallization has been also investigated as a
technique to improve chemical and physical properties of
powders including mechanical strength and flow properties.
For instance, compression properties of paracetamol form I
have been improved by cocrystallization with theophylline,
oxalic acid, naphthalene, and phenazine.136 Hiendrawan et al.
obtained cocrystals of paracetamol and 5-nitroisophtalic acid
using the solvent evaporation method. The tableting experi-
ments showed that the formed cocrystal has superior
tabletability properties compared to both paracetamol and
the coformer.137 The carbamazepine and saccharin cocrystal
was shown to be denser compared to pure carbamazepine.
Moreover, higher tensile strength compared to pure
carbamazepine was obtained at any compaction pressure.
Heckel analysis of the carbamazepine and cocrystal revealed
that plastic deformation in the cocrystal was started at lower
compression, leading to higher compaction.138
3.6. Taste Masking. Quick disintegrating tablets with rapid
dissolution are required for preparing oral disintegrating
tablets. This strategy enables the use of tablets without the
need for chewing or water intake, which broadens the
spectrum of the drug users to geriatric, pediatric, and traveling
patients with no access to water. However, readily disintegrat-
ing tablets necessitate the use of taste masking agents to
improve the patients’ experience. So far, the use of sugar-based
excipients has been the main approach. On the other hand,
poor dissolution rate can be another limiting factor in
developing oral disintegrating formulations. Thus, a greater
advantage could be achieved using an approach for improving
dissolution with tablet sweetening agents.
Cocrystallization could be a promising strategy for
improving the dissolution rate using sugar-based coformers.
Arafa et al. have done so by using sucralose as a coformer for
preparing cocrystals of hydrochlorothiazide. The produced
cocrystal got the benefits of increased dissolution rate and taste
masking, simultaneously.139 Maeno et al. reported a new
cocrystal of paracetamol with trimethylglycine (TMG) with
improved tabletability, compression, and dissolution proper-
ties. Moreover, the taste sensing experiments revealed the
sweetness of the formulation due to the presence of TMG in
the structure.140 Theophelline is known for its bitter taste;
hence, current marketed solid and oral formulations have been
formulated using artificial sweeteners such as vanilla, sodium
glutamate, sodium saccharin, and d-sorbitol. A 1:1 stoichio-
metric cocrystal of theophelline and saccharine was prepared
via liquid assisted grinding. The prepared cocrystal showed
enhanced dissolution and sweetness at the same time based on
the automated sweetness tasting machine used in this study.141
Nine cocrystals of propiverine were generated by mixing it with
organic acid solutions. The results of the use of a taste sensor
showed that propiverine salicylic acid cocrystals are less bitter
than propiverine hydrochloride. The authors illustrated both
improved aqueous solubility and taste masking, simultane-
ously.142
3.7. Enabling in Process Separation and Purification.
Lee et al. demonstrated a continuous cocrystallization process
at 90 mL/min scale for the manufacture of phenazine−vanillin
cocrystals for the purpose of preferentially separating vanillin
from its mother liquor.143 Billot et al. reported on an slurry
based method for the manufacture of an API cocrystal at pilot
plant scale to provide for purification of the API, with
subsequent cleavage of the cocrystal to release the API product
also demonstrated.11
3.8. Generation/Extension of Intellectual Property.
Intellectual property (IP) is vital for pharmaceutical
companies. IP protection of new ideas, inventions, processes,
or products enables the exclusivity on the manufacture and
commercialization of pharmaceutical services or products. IP is
protected in law by, for example, patents, copyright, and
trademarks, which enable individuals or organizations/
companies to earn recognition or financial benefit from their
own work or investment in a creation. Specifically, patents are
a recognition for an invention, which must satisfy the criteria of
global novelty, nonobviousness, and industrial or commercial
application. Patent life cycle management of drugs or drug
products is a critical activity that pharmaceutical companies
have to deal with to ensure they keep their drugs in the market
as long as possible.
Screening of novel solid forms of marketed drugs, including
polymorphs, salts, and cocrystals provides the opportunity to
grant new IP on those drugs and extend their patent life
cycle.144 Pharmaceutical cocrystals possess regulatory and IP
advantages which confer them with unique opportunities,
advantages, and challenges.145,146 FDA has recently issued
revised draft guidance on the classification of pharmaceutical
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cocrystals for industry, which states that from a regulatory
perspective, drugs designed to contain a new cocrystal are
considered analogous to a new polymorph of the API. This
guidance takes novel cocrystals to be considered as new drug
substances rather than drug product intermediates, which
promotes their independent patentability as novel solid forms.
Cocrystals bear also the potential to provide meaningful IP
extension to existing drugs in the market after the expiration of
the original patent, playing an important role in drug lifecycle
management. Figure 8 shows an increasing trend in patent
submissions for novel cocrystals and cocrystal preparation
methods between 2004 and 2017.
Cocrystals also possess important scientific advantages.
Some of these advantages link to the availability of a wide
number of potential complementary molecules (coformers) to
cocrystallize with the drug molecules. This maximizes the
number of new cocrystals that might be discovered for a
particular drug with suitable physicochemical properties (e.g.,
solubility, bioavailability, physical stability).2 As neither of the
APIs of coformers needs to have ionizable functional groups in
their molecular structures, which is a prerequisite for salt
formation, this opens up a larger array of possibilities for the
generation of novel solid state forms of APIs as cocrystals. That
in turn promotes the possibility for IP extension of the existing
drugs currently in the market.
4. CONCLUSIONS
Cocrystallization offers one of the most promising approaches
to improve physicochemical properties of APIs. A wide range
of options exist to prepare cocrystals ranging from routine lab
scale synthesis methods to potentially large scale continuous
production methods. This review offers standard descriptions
and examples of established and emerging cocrystal prepara-
tion routes. Moreover, detailed insight is given on the
proposed mechanisms of cocrystallization in different
techniques. As cocrystals continue to gain interest and prove
their value, the range of demonstrated cocrystal application
areas continues to expand. All demonstrated application areas
for pharmaceutical cocrystals are included in this review with
the aim of highlighting the wide ranging potential of these
materials. It is anticipated that cocrystals will become more and
more routine in pharmaceutical development as their benefits
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Day, G. M.; Gladden, L. F. Testing the sensitivity of terahertz
spectroscopy to changes in molecular and supramolecular structure: a
study of structurally similar cocrystals. Cryst. Growth Des. 2009, 9 (3),
1452−1460.
(48) Lu, E.; Rodriguez-Hornedo, N.; Suryanarayanan, R. A rapid
thermal method for cocrystal screening. CrystEngComm 2008, 10 (6),
665−668.
(49) Willart, J.; Descamps, M. Solid state amorphization of
pharmaceuticals. Mol. Pharmaceutics 2008, 5 (6), 905−920.
(50) Trask, A. V.; Motherwell, W. S.; Jones, W. Solvent-drop
grinding: green polymorph control of cocrystallisation. Chem.
Commun. 2004, 7, 890−891.
(51) Daurio, D.; Medina, C.; Saw, R.; Nagapudi, K.; Alvarez-Nuñ́ez,
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